Bristol-myers Squibb Compnay

Medarex Inc.

Corixa Corporation

Tseng-hui Timothy Chen

Paul O Sheppard

Mohan Srinivasan

David J King

Christopher Robert Bebbington

Josephine M Cardarelli

Brigitte Devaux

Francis J Carr

Mark F Maurer

Indrani Chakraborty

Sarah Lee Pogue

Stephen Williams

Daniel F Ardourel

Susan H Julien

Brian Frederick Schmidt

David King

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.

Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)

Novel synthetic leader peptides have been identified. The leader peptides have use in a method of enhancing the secretion of a recombinant polypeptide produced in a host cell. Polynucleotides encoding the novel leader peptides and a method of designing the polynucleotides are described.

Leader peptides for enhancing secretion of recombinant protein from a host cell

Growing community of inventors

Burlingame, CA, United States of America

Tseng-hui Timothy Chen